but it has not been pursued for many years due to safety concerns, including the risk of fatality. 6 Oral immunotherapy for food allergy was first published nearly a century ago 7 and has been subject to more intensive investigation in the last 20 years. 8 Epicutaneous immunotherapy is a novel alternative that has garnered much interest as a potentially safer approach for treating food allergies.
| E ARLY INVE S TI G ATI ON S IN EPICUTANEOUS IMMUNOTHER APY
Early epicutaneous approaches entailed disrupting the outer layer of skin prior to allergen application. This layer, the stratum corneum, is comprised of cornified keratinocytes embedded in a lipid-rich matrix conferring low permeability to environmental microbes, antigens, and toxins. Different methods for disrupting the skin were employed, including scratching with a needle (scarification), adhesive tape stripping, or other methods of abrasion. In addition to increasing allergen passage across the skin, disruption of the epidermis in this way induced a pro-inflammatory response whereby keratinocytes are activated to secrete alarmins and various cytokines and chemokines with the potential to increase antigen uptake and maturation of dendritic cells. 9 Scattered reports detailing the effects of allergen administration via the skin for the treatment of allergic disorders were published in the early 20th century. 10 The first case report of epicutaneous immunotherapy to treat asthma triggered by horsehair was published in 1921. 11 Administration of pollen extract on scarified skin as a method of allergic rhinitis treatment was reported to be effective in 1936. 12 Additional studies from Europe in the 1950s-1960s can be found in the medical literature citing promising results of epicutaneous pollen administration in relieving allergy symptoms, with side effect profiles more favorable than conventional subcutaneous immunotherapy. [12] [13] [14] [15] [16] [17] However, epicutaneous approaches were not further pursued for several decades until a resurgence of interest occurred in recent years.
In 2009, a randomized trial of an epicutaneous patch containing 12 pollen extracts was published, showing that subjects receiving active treatment experienced significant symptom improvements compared to placebo. 18 The same group also published a phase I/ II randomized, double-blind, placebo-controlled study that included 132 adults with grass-induced allergic rhinitis. 19 Subjects were allocated to receive 1 of 3 treatment doses or placebo. Skin tape stripping was performed prior to patch placement for 8 hours, and subjects were treated with a total of 6 patches: 1 patch pre-pollen season and 5 weekly patches during the pollen season. The primary end-point was a patient-reported outcome of symptom improvement using a visual analog scale. A dose response was seen, with the greatest efficacy observed in the high-dose treatment group. Local side effects were common, but decreased over time. Systemic reactions leading to study dropout occurred in 8% of study patients, but were all reported to be World Allergy Organization (WAO) grade 1-2 in severity. A pediatric study that included 15 children also demonstrated efficacy and safety of once-a-week patch placement for 12 weeks during the grass pollen season, further supporting this approach as a novel treatment for pollen allergies. 20 
| EPIDERMAL DELIVERY SYS TEM (EPI CUTANEOUS VIA S KIN ® PATCH-E VP)
In recent years, epicutaneous immunotherapy in food allergy has been pursued using a novel product that employs occlusion to increase allergen delivery across intact skin, the Epicutaneous 
| EPI CUTANEOUS VIA S K IN ® PATC H (E VP) IN MURINE MODEL S OF I G E-MED IATED FOOD ALLERGY
Potential efficacy and mechanisms of effect of EPIT have been explored using animal models. Utilizing a murine model of peanut allergy, repeated application of the EVP for 8 weeks resulted in
The epicutaneous patch forms a condensation chamber that contains allergenic protein on its inner surface. When it is applied to intact skin, the skin's natural water loss solubilizes and releases allergen, which penetrates the stratum corneum and is then taken up by Langerhans cells that process and transport the allergen to regional lymph nodes where immune responses are initiated and SLIT induced a lesser but significant number of Tregs bearing homing receptors to the skin and gut ( Figure 2) . 28 Additional studies demonstrate that the epicutaneous route induces Foxp3+ and LAP+
Tregs that bear homing receptors to the gut, lung, and skin and that protection from food-induced anaphylaxis occurs via a TGF-betadependent mechanism. EPIT OIT SLIT Naive Sham injected into mice that then underwent a protocol to sensitize them to peanut and house dust mite. The mice were then challenged, and those mice receiving Tregs from the EPIT-treated mice did not develop new sensitizations whereas mice receiving Tregs from untreated mice developed sensitivity to peanut and house dust mite, demonstrating that this protective effect was Treg-dependent. 29 These results suggest that EPIT may be not only effective for the treatment of established allergic disease, but may also have a role in influencing future sensitization, for example, the atopic march.
| EPI CUTANEOUS VIA S K IN ® PATCH IN CLINIC AL TRIAL S
To date, results from 4 clinical trials examining EVP for milk and peanut allergies have been published in peer-review form, 1 for milk and 3 for peanut. One of the peanut studies reports only safety data, whereas the other studies provide information on both safety and efficacy.
There are several larger-scale studies that are ongoing which will provide a more robust assessment of safety and efficacy in the near future.
| Safety
The first EPIT study was performed in children 3 months to 15 years of age with a history of systemic allergic reactions to milk. 21 Nineteen subjects were randomized 1:1 to receive active Viaskin patch (1 mg milk powder) or placebo (1 mg glucose). Patches were applied for 48 hours, 3 times per week for 3 months. Active treated subjects had higher rates of local, patch site symptoms, but there were no interruptions in treatment due to adverse events (AEs). No serious AEs and no epinephrine use were reported in this study.
Three studies examining EPIT for peanut allergy, with a total of 395 subjects, have been published. Results from these studies demonstrate a favorable safety profile, with no serious AEs and no non-anaphylactic gastrointestinal AEs. The first was a randomized, double-blind, placebo-controlled dose-ranging phase Ib study where 100 subjects aged 6-50 years with peanut allergy were enrolled. 30 Subjects were randomized 4:1 active:placebo to 20, 100, 250, or 500 mcg or placebo patch at 24-or 48-hour intervals for 2 weeks (500 mcg was not used in children). The second was a phase IIb, multinational, randomized, controlled dose-ranging trial where 221 subjects were randomized (1:1:1:1) to receive a daily epicutaneous patch containing 50, 100, or 250 mcg of peanut protein or placebo for 12 months. 31 And the third was a NIH-sponsored phase II, multicenter, double-blind, randomized, placebo-controlled trial that enrolled 74 subjects aged 4-25 years who received a daily epicutaneous patch containing 100 or 250 mcg of peanut protein or placebo
(1:1:1 randomization) for 52 weeks. 32 Adverse events primarily included mild symptoms localized to the patch sites. When treatment was needed, topical treatment with corticosteroids and/or oral antihistamines was sufficient to relieve symptoms. Local patch site reactions tended to be more frequent in the active vs placebo cohort (84% vs 60%, P = .21). 30 Fewer local reactions were seen with the 24-hour patch placement compared to 48 hours, 30 and overall, more frequent symptoms were reported for the 250 mcg dose compared to 100 mcg. 30, 32 Local AEs often decreased over time and did not impede continuation of treatment. 31 AEs outside of the patch site were uncommon, and no significant differences were reported between active doses as compared to the placebo. 30, 32 In addition, no differences in other safety parameters measured (including vital signs, physical examination, atopic dermatitis severity, peak expiratory flow/FEV1, and clinical laboratory results) were reported. 30 High adherence rates were reported in the peanut studies (all > 96%). [30] [31] [32] In addition, a low rate of dropouts occurred across the 3 peanut EPIT studies. In the phase Ib trial, 1 placebo and 3 active subjects withdrew early. 30 Three (1 placebo and 2 active) were withdrawn for treatment-related AEs. In the NIH-sponsored phase II trial, 3 placebo and 3 active patients withdrew early, with only 1 in the active group due to treatment-related AEs. 32 In the large-scale phase IIb study, the dropout rate for treatment-related AEs was 0.9%. 31 Results to date demonstrate a high-safety profile, with majority of AEs being mild and localized to the skin patch site ( 
| Efficacy
The first pilot study examined the efficacy of EPIT to treat milk allergy. 21 Children aged To date, 2 double-blind, randomized, placebo-controlled studies have assessed efficacy of EPIT for peanut allergy. One phase IIb doseranging trial enrolled subjects with peanut allergy from 22 centers in the United States and Europe. 31 Eligible subjects were 6-55 years of age who had an eliciting dose less than or equal to 300 mg peanut protein at the baseline double-blind, placebo-controlled food challenge (DBPCFC) using the PRACTALL-recommended dosing schedule, that is, 1, 3, 10, 30, 100, and 300 mg. 34 The primary endpoint was an eliciting dose at the 12-month DBPCFC of 1000 mg peanut protein or greater (~4 peanuts) or a 10-fold or greater increase over the eliciting dose at the baseline DBPCFC. A total of 221 subjects were randomized (1:1:1:1) to receive a daily epicutaneous patch containing 50, 100, or 250 mcg of peanut protein or placebo.
Subjects < 12 years of age had the patch applied to the upper central back area, and those 12 years of age and older applied the patch to the inside of the upper arm. The median age of subjects was 11 years, and 93.7% completed the trial. At the 12-month DBPCFC, a significant absolute difference in response rate was observed between the highest dose group and placebo (50% vs 25%, P = .01). An age interaction was seen in the highest dose group, with a significant response rate seen in the 6-to 11-year-old subgroup (53.6% active vs 19.4% placebo, P = .008). The median cumulative reactive dose in this group overall increased from 30 mg to 400 mg of peanut protein (one-tenth to one and one-third peanuts) in 1 year. No difference was seen in the adolescent/adult cohort.
The authors noted that the results may have been affected by a higher-than-expected placebo response rate, given that one of the primary end-point parameters of 10-fold or greater increase in eliciting dose may not have been stringent enough at the lower doses of the DBPCFC. In addition, this end-point may not be clinically meaningful as such a small incremental increase in reactive dose may not be sufficient to provide protection in case of true accidental exposures, for example, change from 1 mg to 10 mg post-treatment dose. The authors also postulated that the age effect observed may be due to differing patch placement location for younger subjects (back) compared to older subjects (upper inner arms). Other possible limitations considered included suboptimal dosing effect for older subjects with higher weight or body surface area, differences in skin characteristics by age, and less immunoplasticity in older participants, which has also been suggested in OIT and SLIT studies.
Immunologic changes included increases in median peanutspecific IgE over the first 3-6 months in all 3 active treatment arms, followed by declines in levels to near baseline by month 12. 31 A progressive 5-fold increase in peanut-specific IgG 4 was observed over the course of the 12-month treatment period. Diminished skin test median wheal diameters were also noted between months 6 and 12 for all 3 active groups.
A 2-year open-label extension trial followed, in which 82.6%
(171) of those completing the initial blinded trial were enrolled. 31 All were transitioned to the 250 mcg patch at month 6 of this extension study. Food challenges were performed at yearly intervals. Thus far, results demonstrate that EPIT shows significant efficacy after 1 year, although inducing less change in the threshold eliciting dose from baseline to 1 year compared to published reports of high-dose OIT (2-4 g daily maintenance dose) for 1 year. However, EPIT efficacy continues to increase with more prolonged treatment (Table 2 ). An age effect has been noted, with improvements seen primarily in children aged 11 years or younger. The clinical findings are associated with significant immunologic changes, including decreases in skin tests and allergen-specific IgE, increases in specific 
| Ongoing studies
Ongoing trials should provide a better understanding of the safety and efficacy of EPIT using the EVP. MILES is a phase I/II study for children with milk allergy aged 2-17 years (ClinicalTrials.gov Identifier: NCT02223182). Phase I was a safety study of 150, 300, and 500 mcg doses versus placebo over 3 weeks in 18 subjects. This part of the study has been completed, and the phase II portion evaluating safety and efficacy of the 3 doses versus placebo for 12 months aims to
Study

Primary outcome Results
Pilot milk EPIT study 21 Increase in CTD after 3 mo
No significant difference in mean CTD in the per-protocol analysis (P = .13): Active-1.77 ± 2.98 mL to 23.61 ± 28.61 mL Placebo-4.36 ± 5.87 mL to 5.44 ± 5.88 mL Phase IIb dose-ranging peanut study 31 Eliciting dose at the 12-mo DBPCFC of (1). 1000 mg peanut protein or greater or (2). 10-fold or greater increase over the eliciting dose at the baseline DBPCFC Response rate: significant difference comparing 250 mcg vs placebo (50% vs 25%, P = .01). Significant response rate seen in the 6-to 11-y-old subgroup (53.6% active vs 19.4% placebo, P = .008).
No difference was seen for the adolescents/ adults.
Open-label extension trial 31 All were transitioned to the 250 mcg patch at month 6 of this extension study; food challenges performed yearly Overall response rate: 1 y-59.7% 2 y-64.5% 61% of the children achieved a CRD ≥ 1000 mg and 39% achieved a CRD ≥ 5000 mg
Phase II peanut study 32 Passing a challenge of 5044 mg or a 10-fold or greater increase in successfully consumed dose as compared to baseline DBPCFC 
| NE X T S TEPS/ADDITIONAL QUE S TIONS
Further exploration of EPIT is needed to improve understanding of the potential role of this approach for food allergy treatment.
Although comparison of published clinical trial data is limited by the heterogeneity in study designs, it appears that EPIT efficacy may be similar to that of SLIT, 37 but efficacy does not reach the levels seen in high-dose OIT. 38, 39 EPIT may be more comparable in efficacy to low-dose OIT, which has been examined in some studies. In a short-term phase II trial of low-dose peanut OIT (300 mg; AR101), which is also being evaluated for commercial distribution, 40 55 subjects (29 AR101, 26 placebo) enrolled, and 79% and 62% of active subjects tolerated 443 mg and 1043 mg cumulative reactive dose at the exit DBPCFC, respectively (median therapy = 22 weeks; mean = 24 weeks). In contrast, 19% and 0% of placebo subjects achieved these parameters (P < .0001). Consistent with other OIT studies, 20% of active subjects dropped out of the study prior to the exit DBPCFC. Ongoing EPIT studies will continue to examine outcomes of longer treatment duration to determine whether efficacy similar to that seen in low-dose OIT can be achieved in larger groups.
In addition, studies will explore whether efficacy is sustained after treatment discontinuation. Identification of biomarkers that would allow for determination of efficacy and predict treatment outcome is essential.
Assuming multiple options will become available to food-allergic individuals, the decision for choosing which approach to use will likely depend on patient-specific factors such as age and allergy his- with low-dose (300 mg) OIT (ie, 3 years of EPIT exposes patients to less peanut protein than a single administration of low-dose OIT).
As suggested in preclinical studies and early clinical trials, the epicutaneous induction of Treg cells may be useful for treating non-IgEmediated disorders as well, for example, Th2-mediated eosinophilic esophagitis and Th1-mediated autoimmune disorders such as relapsing multiple sclerosis. 43 Future studies should aim to explore this potential, elucidate mechanisms of effect in humans, and provide more robust data regarding safety, efficacy, and durability of effects. 
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